Clinical Implications of Prostaglandin and Thromboxane A2Formation
- 15 September 1988
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 319 (11) , 689-698
- https://doi.org/10.1056/nejm198809153191106
Abstract
(First of Two Parts)THE prostaglandins and thromboxane A2 are biologically active metabolites of arachidonic acid.1 , 2 Their actions and the pharmacologic agents that influence their formation affect almost every aspect of medical practice.The interactions of platelets with the vessel wall in catastrophic events in the coronary and cerebral arteries, as well as in diseases of smaller arterial vessels, have drawn attention to the participation of thromboxane A2 and prostacyclin (prostaglandin I2) in these pathophysiologic processes. Similarly, important medical consequences follow from the participation of prostaglandins in the pathophysiologic activities of the kidney, the mast cell, . . .Keywords
This publication has 98 references indexed in Scilit:
- Aspirin in Cardiovascular DiseaseDrugs, 1988
- Platelet Activation in Unstable Coronary DiseaseNew England Journal of Medicine, 1986
- Dose-Related Kinetics of AspirinNew England Journal of Medicine, 1984
- Increased Prostacyclin Biosynthesis in Patients with Severe Atherosclerosis and Platelet ActivationNew England Journal of Medicine, 1984
- Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease.Circulation, 1983
- A Platelet-Inhibitor-Drug Trial in Coronary-Artery Bypass OperationsNew England Journal of Medicine, 1982
- Inhibition of Prostacyclin and Platelet Thromboxane A2after Low-Dose AspirinNew England Journal of Medicine, 1981
- Increased Production of Prostaglandin D2 in Patients with Systemic MastocytosisNew England Journal of Medicine, 1980
- A double blind placebo controlled crossover study of prostacyclin in manLife Sciences, 1979
- A Randomized Trial of Aspirin and Sulfinpyrazone in Threatened StrokeNew England Journal of Medicine, 1978